Abeona Therapeutics Analyst Ratings
Abeona Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest Abeona Therapeutics (ABEO) rating was a reiterated with a price target of $0.00 to $38.00. The current price Abeona Therapeutics (ABEO) is trading at is $3.95, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/24/2023 | 862.03% | Cantor Fitzgerald | → $38 | Reiterates | Overweight → Overweight |
| 07/13/2023 | 862.03% | Cantor Fitzgerald | → $38 | Reiterates | Overweight → Overweight |
| 05/24/2023 | 406.33% | Alliance Global Partners | → $20 | Reiterates | → Buy |
| 11/14/2022 | 51.9% | SVB Leerink | $5 → $6 | Maintains | Market Perform |
| 11/08/2022 | 912.66% | Cantor Fitzgerald | $22 → $40 | Maintains | Overweight |
| 08/11/2022 | 26.58% | SVB Leerink | $1 → $5 | Maintains | Market Perform |
| 11/30/2021 | -74.68% | SVB Leerink | $5 → $1 | Downgrades | Outperform → Market Perform |
| 11/29/2021 | 1.27% | HC Wainwright & Co. | $5 → $4 | Maintains | Buy |
| 07/19/2021 | 26.58% | HC Wainwright & Co. | $8 → $5 | Maintains | Buy |
| 11/25/2020 | 102.53% | HC Wainwright & Co. | $11 → $8 | Maintains | Buy |
| 11/11/2020 | 1.27% | Cantor Fitzgerald | → $4 | Upgrades | Neutral → Overweight |
| 11/10/2020 | 26.58% | SVB Leerink | $8 → $5 | Maintains | Outperform |
| 09/18/2020 | 26.58% | B. Riley Securities | → $5 | Initiates Coverage On | → Buy |
| 05/08/2020 | 77.22% | RBC Capital | $11 → $7 | Maintains | Outperform |
| 03/18/2020 | 178.48% | RBC Capital | $14 → $11 | Maintains | Outperform |
| 02/10/2020 | 51.9% | SVB Leerink | → $6 | Maintains | Outperform |
| 12/30/2019 | 178.48% | HC Wainwright & Co. | $15 → $11 | Reiterates | → Buy |
| 08/15/2019 | — | Maxim Group | Downgrades | Buy → Hold | |
| 08/12/2019 | -49.37% | Cantor Fitzgerald | $29 → $2 | Downgrades | Overweight → Neutral |
| 08/12/2019 | 279.75% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 07/26/2019 | — | Mizuho | Downgrades | Buy → Neutral | |
| 11/13/2018 | 608.86% | Citigroup | $32 → $28 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/24/2023 | 862.03% | 坎託·菲茨傑拉德 | → 38 美元 | 重申 | 超重 → 超重 |
| 07/13/2023 | 862.03% | 坎託·菲茨傑拉德 | → 38 美元 | 重申 | 超重 → 超重 |
| 05/24/2023 | 406.33% | 聯盟全球合作伙伴 | → 20 美元 | 重申 | → 購買 |
| 11/14/2022 | 51.9% | SVB Leerink | 5 美元 → 6 美元 | 維護 | 市場表現 |
| 2022 年 8 月 11 日 | 912.66% | 坎託·菲茨傑拉德 | 22 美元 → 40 美元 | 維護 | 超重 |
| 08/11/2022 | 26.58% | SVB Leerink | 1 美元 → 5 美元 | 維護 | 市場表現 |
| 2021 年 11 月 30 日 | -74.68% | SVB Leerink | 5 美元 → 1 美元 | 降級 | 跑贏大盤 → 市場表現 |
| 11/29/2021 | 1.27% | HC Wainwright & Co. | 5 美元 → 4 美元 | 維護 | 購買 |
| 07/19/2021 | 26.58% | HC Wainwright & Co. | 8 美元 → 5 美元 | 維護 | 購買 |
| 11/25/2020 | 102.53% | HC Wainwright & Co. | 11 美元 → 8 美元 | 維護 | 購買 |
| 11/11/2020 | 1.27% | 坎託·菲茨傑拉德 | → 4 美元 | 升級 | 中性 → 超重 |
| 11/10/2020 | 26.58% | SVB Leerink | 8 美元 → 5 美元 | 維護 | 跑贏大盤 |
| 09/18/2020 | 26.58% | B. 萊利證券 | → 5 美元 | 啓動覆蓋開啓 | → 購買 |
| 05/08/2020 | 77.22% | 加拿大皇家銀行資本 | 11 美元 → 7 美元 | 維護 | 跑贏大盤 |
| 2020 年 3 月 18 日 | 178.48% | 加拿大皇家銀行資本 | 14 美元 → 11 美元 | 維護 | 跑贏大盤 |
| 2020 年 10 月 2 日 | 51.9% | SVB Leerink | → 6 美元 | 維護 | 跑贏大盤 |
| 2019 年 12 月 30 日 | 178.48% | HC Wainwright & Co. | 15 美元 → 11 美元 | 重申 | → 購買 |
| 08/15/2019 | — | Maxim 集團 | 降級 | 買入 → 持有 | |
| 08/12/2019 | -49.37% | 坎託·菲茨傑拉德 | 29 美元 → 2 美元 | 降級 | 超重 → 中性 |
| 08/12/2019 | 279.75% | HC Wainwright & Co. | → 15 美元 | 啓動覆蓋開啓 | → 購買 |
| 07/26/2019 | — | 瑞穗 | 降級 | 買入 → 中性 | |
| 11/13/2018 | 608.86% | 花旗集團 | 32 美元 → 28 美元 | 維護 | 購買 |
What is the target price for Abeona Therapeutics (ABEO)?
Abeona Therapeutics（ABEO）的目標價格是多少？
The latest price target for Abeona Therapeutics (NASDAQ: ABEO) was reported by Cantor Fitzgerald on August 24, 2023. The analyst firm set a price target for $38.00 expecting ABEO to rise to within 12 months (a possible 862.03% upside). 5 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2023年8月24日公佈了Abeona Therapeutics（納斯達克股票代碼：ABEO）的最新目標股價。該分析公司將目標股價定爲38.00美元，預計ABEO將在12個月內上漲至862.03％（可能上漲862.03％）。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Abeona Therapeutics (ABEO)?
分析師對Abeona Therapeutics（ABEO）的最新評級是多少？
The latest analyst rating for Abeona Therapeutics (NASDAQ: ABEO) was provided by Cantor Fitzgerald, and Abeona Therapeutics reiterated their overweight rating.
Abeona Therapeutics（納斯達克股票代碼：ABEO）的最新分析師評級由坎託·菲茨傑拉德提供，Abeona Therapeutics重申了他們的增持評級。
When is the next analyst rating going to be posted or updated for Abeona Therapeutics (ABEO)?
Abeona Therapeutics（ABEO）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Abeona Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Abeona Therapeutics was filed on August 24, 2023 so you should expect the next rating to be made available sometime around August 24, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與Abeona Therapeutics的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Abeona Therapeutics的最後一次評級是在2023年8月24日提交的，因此你應該預計下一個評級將在2024年8月24日左右公佈。
Is the Analyst Rating Abeona Therapeutics (ABEO) correct?
分析師對Abeona Therapeutics（ABEO）的評級正確嗎？
While ratings are subjective and will change, the latest Abeona Therapeutics (ABEO) rating was a reiterated with a price target of $0.00 to $38.00. The current price Abeona Therapeutics (ABEO) is trading at is $3.95, which is within the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但Abeona Therapeutics（ABEO）的最新評級得到了重申，目標股價爲0.00美元至38.00美元。Abeona Therapeutics（ABEO）目前的交易價格爲3.95美元，在分析師的預測區間內。
